For that reason, Novera Glow is manufactured according to rigorous quality standards intended to support consistency across laboratory applications: Analytical verification
Specifically, NICE suggests considering a DPP-4 inhibitor as a second agent when: The patient has a high risk of hypoglycaemia (making sulfonylureas less suitable) Weight management is a concern and a sulfonylurea's weight-gaining effects are undesirable An SGLT-2 inhibitor is contraindicated or not tolerated NICE NG28 recommends that in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, an SGLT-2 inhibitor should generally be prioritised often alongside or instead of metformin due to its organ-protective benefits
Heres the thing, Cysters: the only real benefit a GLP-1 medication like Ozempic is short-term weight loss
Amano, T., Nishihira, J
Disclaimer: The content on this page is meant for informational purposes and is not, under any circumstances, supposed to be treated as a substitute for any medical advice, diagnosis, or treatment
Microdosing GLP-1 medications lacks clinical evidence, meaning doctors dont have enough reliable data to confirm whether lower than approved doses are effective